Modern treatment of multiple sclerosis.doc

 PAGE \* MERGEFORMAT 14 Modern treatment of multiple sclerosis Keywords:: multiple sclerosis pathogenesis treatment Multiple sclerosis (mS) is the cNS chronic demyelinating disease of unknown etiology and pathogenesis [1]. Worldwide there are about 1 million young adults this disease [2]. First, the decision-making and treatment of diseases related to classification and characteristics of mS treatment aimed at preventing the progress of acute deterioration and remission of relapse and late symptomatic and supportive treatment to alleviate the pain caused by nerve dysfunction. mS course of the standardization of classification has been made in the same [3]: (1) relapsing - remitting MS (relapse-remitting, rR): acute onset recovery, relapse between the two in stable condition; (2) secondary-progressive: rR patients and progressive deterioration of neurological symptoms, with or without acute relapse; (3) primary-progressive: after onset of illness showed a continuous gradual deterioration; (4) progressive relapsing type: gradual progress after onset of illness, and between the recurrence. rR the most common type mS, half of patients over a period of time can be transformed into secondary progressive MS. About 10% of patients for the primary progressive type, their age of onset is too large (40 ~ 60 years), and often progressive myelopathy, mRI show gadolinium contrast agent (gadolinium) enhancing lesions in secondary progressive than less, cSF also are seldom found in inflammatory changes. Progress in relapsing rare. rR response to treatment based on the best progressive poor response. About 10% of patients showed a benign course of disease. Instructions and the rapid deterioration of disease with poor prognosis indications: (1) immediately after onset showed progressive course of disease; (2) movements and cerebellar signs appeared; (3) the recurrence interval period of two previous short; (4) relapse after recovery compared with poor; (5) the initial onse